Carregant...
Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus
Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally. The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next five most common cancer-causing HPV types (HPV 31/33/45/52/58) after HPV 16/18. Phase III clinical studies have demonstrated h...
Guardat en:
| Publicat a: | Infect Drug Resist |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6613616/ https://ncbi.nlm.nih.gov/pubmed/31308715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S178381 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|